Interview of Mario Caria by Hannah Kuchler from the Financial Times
KUSTE Biopharma participated to several conferences
At KUSTE we focus on two therapeutics areas
Bladder Pain Syndrome/IC
Kuste develops therapies for unmet medical inflammatory urological diseases such as Bladder Pain Syndrome/Interstitial Cystitis
Inflammatory Bowel Diseases
KUSTE prioritises areas of GI associated with high unmet need, such as inflammatory bowel disease.
Two small peptides acting in the JNK inhibition, have reached up to Phase 3 results.
We are always Focused on
Discover the team
Read more about our Scientific Advisory Board and Management Team…